ERBB2 and non-small cell lung carcinoma: In August 2022, the Food and Drug Administration (FDA) granted accelerated approval for trastuzumab deruxtecan (T-DXd) in patients with previously treated, unresectable, or metastatic HER2-mutated NSCLC based on the DESTINY-Lung02 trial [1, 2].